Journal
ONCOGENE
Volume 41, Issue 3, Pages 444-458Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-021-01903-5
Keywords
-
Funding
- National Cancer Institute [F99CA212225, 5R01CA17640105, 5R01CA18256905, 5R01CA21732903]
- Sidney Kimmel Cancer Center [5P30CA056036-17]
- Laboratory Animals, MetaOmics, Translational Pathology shared resources
- Prostate Cancer Foundation
Ask authors/readers for more resources
The tumor suppressor gene TP53 is frequently mutated in prostate cancer, with missense mutations at specific hotspots like R273. Mutant p53 variants R273C and R273H exhibit similar loss of DNA binding and transcriptional function in the absence of wild-type p53, but show distinct transcriptional profiles when wild-type p53 is present. Additionally, modeling of heterozygous expression of these mutants results in different phenotypic outcomes in vitro and in vivo, highlighting the context-dependent pro-tumorigenic role of mutant p53 in prostate cancer progression.
The tumor suppressor gene TP53 is the most frequently mutated gene in numerous cancer types, including prostate cancer (PCa). Specifically, missense mutations in TP53 are selectively enriched in PCa, and cluster to particular hot spots in the p53 DNA binding domain with mutation at the R273 residue occurring most frequently. While this residue is similarly mutated to R273C-p53 or R273H-p53 in all cancer types examined, in PCa selective enrichment of R273C-p53 is observed. Importantly, examination of clinical datasets indicated that TP53 heterozygosity can either be maintained or loss of heterozygosity (LOH) occurs. Thus, to mimic tumor-associated mutant p53, R273C-p53 and R273H-p53 isogenic PCa models were developed in the presence or absence of wild-type p53. In the absence of wild-type p53, both R273C-p53 and R273H-p53 exhibited similar loss of DNA binding, transcriptional profiles, and loss of canonical tumor suppressor functions associated with wild-type p53. In the presence of wild-type p53 expression, both R273C-p53 and R273H-p53 supported canonical p53 target gene expression yet elicited distinct cistromic and transcriptional profiles when compared to each other. Moreover, heterozygous modeling of R273C-p53 or R273H-p53 expression resulted in distinct phenotypic outcomes in vitro and in vivo. Thus, mutant p53 acts in a context-dependent manner to elicit pro-tumorigenic transcriptional profiles, providing critical insight into mutant p53-mediated prostate cancer progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available